Literature DB >> 11536167

N-linked carbohydrates in tyrosinase are required for its recognition by human MHC class II-restricted CD4(+) T cells.

F Housseau1, A Moorthy, D A Langer, P F Robbins, M I Gonzales, S L Topalian.   

Abstract

Glycosylation of mammalian proteins is known to influence their intracellular trafficking, half life, and susceptibility to enzymatic degradation. Rare instances of natural T cell epitopes dependent upon glycosylation for recognition have been described. We report here on human CD4(+) T lymphocyte cultures and clones from two melanoma patients that recognize the melanoma-associated Ag tyrosinase in the context of HLA-DR4 and -DR8. These T cells recognize tyrosinase, normally a heavily glycosylated molecule, when expressed constitutively in melanoma cells or in COS-7 transfectants pulsed as lysates onto autologous APC. However, these T cells fail to recognize tyrosinase expressed in bacteria, nor do they react with overlapping peptides covering full-length tyrosinase, suggesting a critical role for glycosylation in the processing and / or composition of the stimulatory epitopes. The requirement for glycosylation was demonstrated by the failure of tyrosinase-specific CD4(+) T cells to recognize tyrosinase synthesized in the presence of glycosylation inhibitors, or deglycosylated enzymatically. Site-directed mutagenesis of each of seven potential N-glycosylation sites showed that four sites were required to generate forms of tyrosinase that could be recognized by individual T cell clones. These data indicate that certain carbohydrate moieties are required for processing the tyrosinase peptides recognized by CD4(+) T cells. Post-translational modifications of human tumor-associated proteins such as tyrosinase could be a critical factor for the development of antitumor immune responses.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11536167     DOI: 10.1002/1521-4141(200109)31:9<2690::aid-immu2690>3.0.co;2-8

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  4 in total

1.  Evaluation of prime/boost regimens using recombinant poxvirus/tyrosinase vaccines for the treatment of patients with metastatic melanoma.

Authors:  Kimberly R Lindsey; Linda Gritz; Richard Sherry; Andrea Abati; Patricia A Fetsch; Lisa C Goldfeder; Monica I Gonzales; Kimberly A Zinnack; Linda Rogers-Freezer; Leah Haworth; Sharon A Mavroukakis; Donald E White; Seth M Steinberg; Nicholas P Restifo; Dennis L Panicali; Steven A Rosenberg; Suzanne L Topalian
Journal:  Clin Cancer Res       Date:  2006-04-15       Impact factor: 12.531

2.  Processing of tumor antigen differentially impacts the development of helper and effector CD4+ T-cell responses.

Authors:  Dannie Bernard; Michael S Ventresca; Laura A Marshall; Carole Evelegh; Yonghong Wan; Jonathan L Bramson
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

3.  Identification and Characterization of Complex Glycosylated Peptides Presented by the MHC Class II Processing Pathway in Melanoma.

Authors:  Stacy A Malaker; Michael J Ferracane; Florence R Depontieu; Angela L Zarling; Jeffrey Shabanowitz; Dina L Bai; Suzanne L Topalian; Victor H Engelhard; Donald F Hunt
Journal:  J Proteome Res       Date:  2016-09-13       Impact factor: 4.466

4.  Natural antigenic peptides from squamous cell carcinoma recognized by autologous HLA-DR8-restricted CD4+ T cells.

Authors:  Hiroaki Kondo; Hiroeki Sahara; Akihiro Miyazaki; Yuki Nabeta; Yoshihiko Hirohashi; Takayuki Kanaseki; Akira Yamaguchi; Naoyuki Yamada; Kazuo Hirayama; Manabu Suzuki; Junji Hamuro; Toshihiko Torigoe; Nobuaki Takahashi; Gen-iku Kohama; Hideyuki Ikeda; Noriyuki Sato
Journal:  Jpn J Cancer Res       Date:  2002-08
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.